Arcadia Biosciences, Inc.
RKDA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $5,045 | $4,454 | $7,418 | $6,780 |
| % Growth | 13.3% | -40% | 9.4% | – |
| Cost of Goods Sold | $2,963 | $2,174 | $6,101 | $8,708 |
| Gross Profit | $2,082 | $2,280 | $1,317 | -$1,928 |
| % Margin | 41.3% | 51.2% | 17.8% | -28.4% |
| R&D Expenses | $53 | $64 | $1,509 | $3,889 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $9,641 | $8,234 | $15,036 | $22,938 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$3,964 | $84 | -$1,221 | $6,771 |
| Operating Expenses | $5,730 | $8,382 | $15,324 | $33,598 |
| Operating Income | -$3,648 | -$6,102 | -$14,007 | -$35,526 |
| % Margin | -72.3% | -137% | -188.8% | -524% |
| Other Income/Exp. Net | -$661 | $781 | $3,193 | $19,394 |
| Pre-Tax Income | -$4,309 | -$5,321 | -$10,814 | -$16,132 |
| Tax Expense | $8 | $8 | $14 | $2 |
| Net Income | -$7,038 | -$13,981 | -$15,376 | -$14,660 |
| % Margin | -139.5% | -313.9% | -207.3% | -216.2% |
| EPS | -5.16 | -11.3 | -26.05 | -30.33 |
| % Growth | 54.3% | 56.6% | 14.1% | – |
| EPS Diluted | -5.16 | -11.3 | -26.05 | -30.33 |
| Weighted Avg Shares Out | 1,363 | 1,237 | 599 | 532 |
| Weighted Avg Shares Out Dil | 1,363 | 1,237 | 599 | 532 |
| Supplemental Information | – | – | – | – |
| Interest Income | $782 | $695 | $289 | $0 |
| Interest Expense | $0 | $0 | $0 | $20 |
| Depreciation & Amortization | $113 | $287 | $479 | $1,045 |
| EBITDA | -$7,499 | -$5,731 | -$14,749 | -$27,710 |
| % Margin | -148.6% | -128.7% | -198.8% | -408.7% |